Getting access to popular weight loss drugs will be simpler and cheaper for some.Health insurer Cigna (CI) announced a new ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

Caremark stood to receive substantial fees for the weight-loss drugs even without excluding Zepbound. Novo Nordisk and Eli Lilly have a duopoly in the booming market for weight-loss drugs ...

Weight loss was about 6% lower in men than in ... or list of covered drugs, as of July 1. Zepbound will be excluded. It’s important to have a range of drugs to treat a disease as widespread ...

In an emailed statement to CBS News Monday, a spokesperson for Novo Nordisk, the maker of Wegovy and Ozempic, said both Wegovy and Zepbound ... the drugs aren't just about weight loss, and pointed ...

Eli Lilly’s weight loss drug Zepbound outperformed competitor Novo Nordisk’s Wegovy, according to a clinical trial funded by Lilly. The SURMOUNT-5 trial, a Phase 3b open-label clinical trial ...

After 72 weeks of treatment, people taking Zepbound lost about 50 pounds, compared with 33 pounds for those taking Wegovy. The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight ...

Zepbound Beats Wegovy for Weight Loss in First Head-To-Head Trial of Blockbuster Drugs People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo ...